medigraphic.com
ISSN 1561-2996 (Digital)
ISSN 0864-0289 (Impreso)

2014, Número 1

<< Anterior Siguiente >>

Rev Cubana Hematol Inmunol Hemoter 2014; 30 (1)


Dosis moderadas de hidroxiurea en niños con drepanocitosis y accidente vascular encefálico. Resultados preliminares

Machín GS, Menéndez VA, Scherle MC, Svarch E, González OA, Arencibia NA, Gutiérrez DA, Lam DRM

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 21-26
Archivo PDF: 43.69 Kb.


RESUMEN

Se trataron 20 niños con anemia drepanocítica, dos ellos con hemoglobinopatía SC y uno con S/â0 talasemia con accidente vascular encefálico o Doppler transcraneal con velocidades del flujo sanguíneo mayor de 170 cm/s. La media de seguimiento fue de 41 ± 19 meses. En los pacientes con accidente vascular encefálico se administraron 25 mg/kg/día de hidroxiurea y se realizó régimen de transfusión crónica por un año. En los niños con Doppler transcraneal patológico se administró la hidroxiurea sola en igual dosis. Hubo una disminución significativa del número de accidentes vasculares encefálicos (p‹0.02) y de la velocidad del flujo sanguíneo en la arteria cerebral media derecha (p‹0.003). En tres niños con velocidades de flujo muy aumentadas en el Doppler transcraneal sin accidente vascular encefálico fue necesario asociar régimen de hipertransfusión por no respuesta al tratamiento. La asociación de hidroxiurea y transfusiones de glóbulos rojos durante un año pueden ser útiles en el tratamiento y prevención del accidente vascular encefálico.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ohene-Frempong K, Weiner SJ, Sleeper LA, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: Rates and risk factors. Blood 1998 Jan;91(1):288-94. PMID: 9414296.

  2. Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med 1978;65(3):461-71. PMID: 717414.

  3. Ballas SK, Kesen MG, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, et al. Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management. Scientific World J. 2012; 2012: 949535. Published online 2012 August 1. PMCID: 3415156.

  4. Sarnaik S, Soorya D, Kim J, Ravindranath Y, Lusher J. Periodic transfusions for sickle cell anemia and CNS infarction. Am J Dis Child 1979 Dec;133(12):1254-7. PMID: 517476.

  5. Sarnaik S, Lusher J. Neurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol 1982 Winter;4(4):386-94. PMID: 7168488.

  6. Scothorn D, Price C, Schwartz D, Terrill C, Buchanan GR, Shurney W, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002 Mar;140(3):348-54. PMID: 11953734.

  7. Castellino SM, Combs MR, Zimmerman SA, Issitt PD, Ware RE. Erythrocyte autoantibodies in paediatric patients with sickle cell disease receiving transfusion therapy: Frequency, characteristics and significance. Br J Haematol 1999 Jan;104(1):189-94. PMID: 10027733.

  8. Harmatz P, Butensky E, Quirolo K, Williams R, Ferrell L, Moyer T, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000 Jul;96(1):76-9. PMID: 10891433.

  9. Adams RJ, Brambilla D,STOP2-Trial-Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005 Dec;353(26):2769-78. PMID:16382063.

  10. Ali SB, Moosang M, King L, Knight-Madden J, Reid M. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Am J Hematol 2011 Oct;86(10):846-50. PMID: 21898530.

  11. Ware R, Aygun R. Advances in the use of Hydroxyurea. Hematology Am Soc Hematol Educ Program 2009;2009:62-69.

  12. DeBaun MR. Secondary prevention of overt strokes in sickle cell disease: therapeutic strategies and efficacy. Hematology Am Soc Hematol Educ Program 2011;2011:427-33.

  13. Zimmerman SA, Schultz WH, Burgett S, Mortier NA, Ware RE. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007 Aug 1;110(3):1043-7. PMID: 17429008.

  14. Aygun B, McMurray MA, Schultz WH, Kwiatkowski JL, Hilliard L, Alvarez O et al Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol 2009 May;145(4):524-8. PMID: 19344396.

  15. Bernaudin F, Verlhac S, Arnaud C, Kamdem A, Chevret S, Hau I, et al. Impact of early transcranial Doppler screening and intensive therapy on cerebral vasculopathy outcome in a newborn sickle cell anemia cohort. Blood 2011 Jan 27;117(4):1130-40. PMID: 21068435.

  16. Ware RE, Helms RW; SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012 Apr 26;119(17):3925-32.

  17. Greenway A, Ware RE, Thornburg CD. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol 2011 Apr;86(4):357-61. PMID: 21442640.

  18. Ware RE, Schultz WH, Yovetich N, Mortier NA, Alvarez O, Hilliard L, et al. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): A Phase III Randomized Clinical Trial for Treatment of Children With Sickle Cell Anemia, Stroke, and Iron Overload. Pediatr Blood Cancer 2011 Dec 1;57(6):1011-7. PMID: 21826782.

  19. Bulas D. Screening children for sickle cell vasculopathy: guidelines for transcranial Doppler evaluation. Pediatr Radiol 2005 Mar;35(3):235-41. PMID: 15703903.

  20. Steinberg MH, Lu ZH, Borton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 2001 Feb 1;89(3):1078-88. PMID: 9028341.

  21. Zimmerman SA, Shultz NH, Davis JS, Pickens CV, Mortier NA, Howard TA et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004 Mar 15;103(6):2039-45. PMID: 14630791.

  22. Svarch E, Machín S, Nieves RM, Mancia de Reyes AG, Navarrete M, Rodríguez H. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean Countries. Pediatr Blood Cancer 2006 Jul;47(1):111-2. PMID: 16550531.

  23. Ferster A, Tariri P, Vermylen C, Sturbois G, Corazza F, Fondu P, et al. Five years of experience with hydroxiurea in children and young adults with sickle cell disease. Blood 2001 Jun 1;97(11):3628-32. PMID: 11369660.

  24. Braga LB, Ferreira AC, Guimaraes M, Nazario C, Pacheco P, Miranda A et al. Clinical and laboratory effects of hydroxiurea in children and adolescents with sickle cell disease: a Portuguese hospital study. Hemoglobin 2005;29(3):171-80. PMID: 16114180.




2020     |     www.medigraphic.com